Price
$87.84+46.18%Social Signal Score
Analyst Ratings
21 analystsRevenue
$357.76M+57.02%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Christopher A. Simon
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 3,009
- Beta
- 0.54
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 3.51
Financials
Revenue
$357.76M+57.0%Net Income
$46.30M+200.8%EBITDA
$102.88M+136.6%Free Cash Flow
$118.89M+227.5%EPS (diluted)
$1.00+233.3%Shares Outstanding (diluted)
46.46M-10.8%Operating Expenses
$135.39MCash & Debt
$260.71MReturn of Capital
$0.00Revenue by Segment (annual)
$2.14BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $1.33B | $97.31M | $2.05 |
| 2025 | $1.36B | $167.68M | $3.31 |
| 2024 | $1.31B | $117.56M | $2.32 |
| 2023 | $1.17B | $115.40M | $2.27 |
| 2022 | $993.20M | $43.38M | $0.85 |
| 2021 | $870.46M | $79.47M | $1.57 |
| 2020 | $988.48M | $76.53M | $1.51 |
| 2019 | $967.58M | $55.02M | $1.07 |
| 2018 | $903.92M | $45.57M | $0.86 |
| 2017 | $886.12M | $-26.27M | $-0.51 |
| 2016 | $908.83M | $-55.62M | $-1.09 |
| 2015 | $910.37M | $16.90M | $0.33 |
| 2014 | $938.51M | $35.15M | $0.68 |
| 2013 | $891.99M | $38.80M | $0.76 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from HAE's reported EPS growth of 7.9% a year over 13 years.
- EPS in 5 years
- $3.02
- Implied price
- $78.43
- Return from $122.86
- -8.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $38.99 — -68.3% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 18 | 22 | 26 | 30 | 34 |
|---|---|---|---|---|---|
| -2.1% | -22.9% | -19.8% | -17.1% | -14.6% | -12.5% |
| 2.9% | -19.0% | -15.7% | -12.8% | -10.3% | -8.0% |
| 7.9% | -15.1% | -11.6% | -8.6% | -5.9% | -3.5% |
| 12.9% | -11.1% | -7.5% | -4.3% | -1.6% | 0.9% |
| 17.9% | -7.2% | -3.4% | -0.1% | 2.8% | 5.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
80+26.32%Social Signal Score
Mentions (40)
- News (RSS)seekingalpha·1d ago·Positive
Pharvaris: Orally Available HAE Therapy Appears To Be Ideal All Court Player
View source ↗ - Newszacks.com·13d ago·Negative
International Markets and Haemonetics (HAE): A Deep Dive for Investors Review Haemonetics' (HAE) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
View source ↗ - Newsmarketbeat.com·15d ago·Negative
Haemonetics Q2 Earnings Call Highlights Haemonetics NYSE: HAE raised its fiscal 2027 revenue growth outlook after reporting double-digit organic growth in its second quarter, but lowered its operating margin expansion forecast as it invests to support an expanded relationship with plasma collector CSL.
View source ↗ - Newsseekingalpha.com·17d ago·Positive
Haemonetics Corporation (HAE) Q2 2027 Earnings Call Transcript Haemonetics Corporation (HAE) Q2 2027 Earnings Call Transcript
View source ↗ - Newszacks.com·17d ago·Positive
Haemonetics Corporation (HAE) Hits Fresh High: Is There Still Room to Run? Haemonetics (HAE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
View source ↗ - Newszacks.com·17d ago·Positive
Haemonetics (HAE) Q2 Earnings and Revenues Surpass Estimates Haemonetics (HAE) came out with quarterly earnings of $1.35 per share, beating the Zacks Consensus Estimate of $1.3 per share. This compares to earnings of $1.27 per share a year ago.
View source ↗ - Newsprnewswire.com·17d ago·Neutral
…e on Investor Relations Website Financial release and supplemental presentation accessible online BOSTON, Nov. 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2027, which ended September 26, 2026, are available on the Company's Investor Relations website at www.haemonetics.com. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m…
View source ↗ - News (RSS)seekingalpha·18d ago·Positive
BioCryst: Solid Q3 Earnings, But Long-Acting HAE Data Due 2027 The Key Catalyst
View source ↗ - News (RSS)seekingalpha·18d ago·Neutral
Haemonetics Q2 2027 Earnings Preview
View source ↗ - Newsseekingalpha.com·18d ago·Neutral
BioCryst: Solid Q3 Earnings, But Long-Acting HAE Data Due 2027 The Key Catalyst BioCryst Pharmaceuticals delivered Q3 2026 results ahead of expectations, maintaining 2026 guidance and highlighting Orladeyo's ongoing growth in a competitive HAE market. BCRX's valuation appears modest at ~3.5x forward P/S and ~11x forward P/E (excluding IPR&D), but future upside depends on pipeline execution, especially navenibart. Management pivots to external innovation, targeting >$1bn revenues by 2030 with Orl…
View source ↗ - Newszacks.com·26d ago·Positive
All You Need to Know About Haemonetics (HAE) Rating Upgrade to Buy Haemonetics (HAE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE —Expands BioCryst portfolio of targeted oral prophylactic therapy options to meet patients' individual needs and preferences—
View source ↗ - News (RSS)seekingalpha·34d ago·Neutral
Haemonetics wins approval of PerQseal Elite vascular closure system
View source ↗ - Newsprnewswire.com·34d ago·Negative
Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System BOSTON, Oct. 19, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval of the PerQseal® Elite vascular closure system for large-bore arterial procedures. The approval expands Haemonetics' portfolio of clinically-differentiated large-bor…
View source ↗ - Newszacks.com·37d ago·Positive
Haemonetics Gains 149.3% in a Year: What's Driving the Rally? HAE shares surged 149.3% in a year, fueled by strong Plasma and MedSurg growth, rising product demand and an upbeat fiscal 2027 revenue outlook.
View source ↗ - Newszacks.com·38d ago·Neutral
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now? HAE's MedSurg growth and NexSys PCS adoption support its prospects, but competitive pressures and unfavorable currency movements pose risks.
View source ↗ - Newszacks.com·40d ago·Positive
Why Haemonetics (HAE) is a Top Momentum Stock for the Long-Term Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newszacks.com·44d ago·Neutral
Strength Seen in Haemonetics (HAE): Can Its 17.5% Jump Turn into More Strength? Haemonetics (HAE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
View source ↗ - Newsglobenewswire.com·45d ago·Negative
Phase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet ZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced tha…
View source ↗ - News (RSS)zerohedge·45d ago·Neutral
…ias develops in the Atlantic, with oil and gas producers shutting in wells and evacuating personnel as the storm tracks toward the Gulf Coast. Shares of Haemonetics (HAE) rise 18% after CSL Plasma expanded its relationship with the maker of blood-processing systems. Spotify Technology SA (SPOT) falls 0.5% as it is being started with a neutral rating and $540 price target at Piper Sandler, which writes that it is “looking for a catalyst” to get more excited about the audio-streaming company. Wolf…
View source ↗ - Newsproactiveinvestors.com·45d ago·Neutral
Haemonetics shares jump as CSL sets 2027 rollout of plasma devices Haemonetics (NYSE:HAE) shares jumped over 13% to $115.20 on Thursday after CSL set out a timetable for moving its US plasma collection centers onto the company's devices. CSL Limited (ASX:CSL), the Australian biotechnology company, expects to finish rolling out Haemonetics' NexSys PCS devices with Persona PLUS technology and related disposables by the end of 2027.
View source ↗ - Newsbarrons.com·45d ago·Neutral
Haemonetics Stock Surges as Plasma Deal Opens Door to More Revenue CSL Plasma plans to use Haemonetics' plasma collection equipment across all existing U.S. centers, expanding the scope of an earlier supply agreement.
View source ↗ - Newsglobenewswire.com·48d ago·Positive
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options
View source ↗ - Newsprnewswire.com·53d ago·Neutral
Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026 BOSTON, Sept. 30, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, November 5, 2026.
View source ↗ - Newszacks.com·59d ago·Positive
Haemonetics (HAE) is a Top-Ranked Momentum Stock: Should You Buy? Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - News (RSS)yahoo·64d ago·Neutral
Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances
View source ↗ - Newsmarketbeat.com·64d ago·Negative
Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances Intellia Therapeutics NASDAQ: NTLA executives outlined plans for a potential launch of its hereditary angioedema treatment, lonvo-z, while discussing the company's ongoing Phase III program in transthyretin amyloidosis and its capital position during a Morgan Stanley event.
View source ↗ - Newsglobenewswire.com·68d ago·Neutral
…26, as the first milestone payment in connection with the previously announced acquisition of Vivasure Medical Limited (“Vivasure”) by Haemonetics Corporation (NYSE: HAE, “Haemonetics”).
View source ↗ - Newszacks.com·74d ago·Negative
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug NTLA's BLA for lonvo-z wins FDA priority review for the treatment of HAE. A decision from the agency is expected by March 10, 2027.
View source ↗ - Newsseekingalpha.com·86d ago·Neutral
BioCryst Pharmaceuticals: Owning Both Sides Of The HAE Preference Curve BioCryst Pharmaceuticals (BCRX) is evolving into a dual-product hereditary angioedema (HAE) franchise, targeting both oral and injectable prophylactic preferences. BCRX's ORLADEYO profit engine supports pipeline funding; Q2 2026 revenue reached $218.3M, with strong gross margins and positive cash flow independent of licensing receipts. The navenibart acquisition positions BCRX to capture injectable-preferring HAE patients, l…
View source ↗ - News (RSS)investing·89d ago·Negative
BioCryst gets Japan approval for HAE drug in young children
View source ↗ - Newsglobenewswire.com·89d ago·Neutral
BioCryst Announces Approval of ORLADEYO® for Pediatric HAE Patients in Japan — Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to
View source ↗ - News (RSS)seekingalpha·93d ago·Neutral
Haemonetics: Worth Speculating On This Recurring Medtech Plasma Model
View source ↗ - Newsseekingalpha.com·93d ago·Negative
Haemonetics: Worth Speculating On This Recurring Medtech Plasma Model Haemonetics is a medtech company that's increasingly generating more recurring revenues with plasma consumables. HAE also has MedSurg, which generates higher margins by selling technologies useful for cardiovascular procedures, for example. As such, these two segments give HAE a durable growth profile. And their recent agreement with CSL could expand on this potential.
View source ↗ - Newsgurufocus.com·96d ago·Neutral
Haemonetics Corp (HAE) Shares Surge 15.9% -- What GF Score of 85 Tells Investors On August 18, 2026, Haemonetics Corp (HAE) shares rose 15.9%, bringing the current price to $104.65. This performance reflects a significant 52-week range, with
View source ↗ - Newszacks.com·96d ago·Positive
Here's Why Haemonetics (HAE) is a Strong Momentum Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - Newszacks.com·97d ago·Positive
Haemonetics (HAE) is a Top-Ranked Value Stock: Should You Buy? The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
View source ↗ - Newszacks.com·100d ago·Positive
HAE Stock Gains on Q1 Earnings & Revenue Beat, Fiscal '27 View Up Haemonetics raises fiscal 2027 revenue guidance after Q1 earnings and sales beat, supported by Plasma growth and stronger cash generation.
View source ↗ - Newszacks.com·103d ago·Neutral
Haemonetics (HAE) Reliance on International Sales: What Investors Need to Know Examine Haemonetics' (HAE) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
View source ↗ - Newsmarketbeat.com·106d ago·Positive
Haemonetics Q1 Earnings Call Highlights Haemonetics NYSE: HAE reported a stronger start to fiscal 2027, with first-quarter revenue rising 6% year over year to $339 million and adjusted diluted earnings per share increasing 4% to $1.14. The company raised its full-year revenue outlook, citing broad-based growth across its MedSurg and apheresis businesses, while maintaining a disciplined stance on assumptions for the remainder of the year.
View source ↗
Earnings
Thu, Feb 4(in 2 months)
Consensus estimate $1.26 per share
Typical surprise +4.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$1.35 vs $1.29beat
- Thu, Aug 6$1.14 vs $1.08beat
- Thu, May 7$1.29 vs $1.28beat
- Thu, Feb 5$1.31 vs $1.27beat
- Thu, Nov 6$1.27 vs $1.12beat
- Thu, Aug 7$1.10 vs $1.01beat
Estimates and results for HAE via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HAE officers and directors.
- Bought
- $99k
- Sold
- $494k
1 trade
2 trades
- Maunsell Farris Maryannesold
- Kroll Mark Wbought
- Strong Stewart Wsold
97 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Lois Frankelhouse · FL21 · disclosed May 25, 2021 (19d later)Sell$1,001 - $15,000
- Lois Frankelhouse · FL21 · disclosed May 25, 2021 (18d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Feb 9, 2021 (15d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Nov 5, 2020 (20d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Oct 13, 2020 (28d later)Sell$1,001 - $15,000
- Lois Frankelhouse · FL21 · disclosed Aug 24, 2020 (10d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jun 16, 2020 (28d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jun 16, 2020 (15d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jun 10, 2020 (26d later)Buy$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Jun 10, 2020 (13d later)Buy$1,001 - $15,000
- Lois Frankelhouse · FL21 · disclosed Jun 22, 2018 (15d later)Sell$1,001 - $15,000
- Lois Frankelhouse · FL21 · disclosed Jun 22, 2018 (8d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
